M. Zhdanava

P. Lefebvre, J. Suh, D. Pilon, 2022, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida

D. Tanton, R. Bailey, M. Duh, 2018, Current medical research and opinion.

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

R. Maziarz, E. Wu, Lei Chen, 2016, International journal of hematologic oncology.

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA

C. Neslusan, P. Lefebvre, K. Joshi, 2021, PharmacoEconomics.

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA

T. Fitzgerald, P. Lefebvre, D. Pilon, 2022, Dermatology and Therapy.

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis

C. François, A. Guérin, M. Zhdanava, 2017, BMC Psychiatry.

Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab

A. Manceur, E. Muser, P. Lefebvre, 2023, Current medical research and opinion.

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.

J. Sheehan, P. Lefebvre, K. Joshi, 2021, The Journal of clinical psychiatry.

Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy

L. Citrome, J. Sheehan, P. Lefebvre, 2021, Journal of medical economics.

Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder

P. Lefebvre, K. Joshi, D. Pilon, 2020, Current medical research and opinion.

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation

M. Alberts, P. Lefebvre, B. Bookhart, 2023, Advances in therapy.

Long-term omalizumab outcomes in chronic idiopathic urticaria: A real-world study.

P. Lefebvre, B. Ortiz, J. Lecocq, 2019, Allergy and asthma proceedings.

Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.

Paul D. Williams, Yongling Xiao, V. Hernandez-Trujillo, 2018, Allergy and asthma proceedings.

Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression

L. Citrome, J. Sheehan, P. Lefebvre, 2021, Advances in Therapy.

Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.

P. Lefebvre, B. Ortiz, J. Lecocq, 2019, Clinical therapeutics.

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study

M. Alberts, P. Lefebvre, B. Bookhart, 2023, International Journal of Clinical Pharmacy.

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study

M. Alberts, P. Lefebvre, B. Bookhart, 2023, Advances in Therapy.

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

S. Feldman, T. Fitzgerald, P. Lefebvre, 2023, Dermatology and Therapy.

Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?

J. Sheehan, P. Lefebvre, K. Joshi, 2019, Journal of affective disorders.

Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy

M. Alberts, P. Lefebvre, B. Bookhart, 2023, Current medical research and opinion.

Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab

A. Manceur, S. Kachroo, D. Pilon, 2023, Current medical research and opinion.

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions

Craig E. Nelson, P. Lefebvre, K. Joshi, 2020, Journal of Managed Care & Specialty Pharmacy.

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans.

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

S802 Persistence Among Patients With Crohn’s Disease Previously Treated With an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent

A. Manceur, B. Goodwin, D. Pilon, 2022, Clinical therapeutics.

Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.

P. Lefebvre, K. Joshi, D. Pilon, 2022, Clinical therapeutics.

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.

P. Lefebvre, B. Ortiz, B. Paknis, 2018, Allergy and asthma proceedings.

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2024, Drugs - real world outcomes.